JAKPot for treating bone loss
Researchers report that JAK inhibitors a class of approved anti-inflammatory drugs prevented bone loss in mice with osteoporosis and two patients with rheumatoid arthritis.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1280 entries already.
Entries by Thomas Gabrielczyk
Mereo BioPharma raise money to back Phase III trials
/in News/by Thomas GabrielczykMereo BioPharma has entered into a $5m convertible equity financing with Novartis and a $28m securities purchase agreement with Aspire Capital Fund.
BIH scientists optimise CRISPR gene scissors
/in News/by Thomas GabrielczykTargeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".
Azafaros BV raises 25m in Series A round
/in News/by Thomas GabrielczykDutch biotech Azafaros B.V. has closed a 25m Series A financing round.
Researchers identify roots of childhood asthma
/in News/by Thomas GabrielczykInfants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.
MaaT Pharma raise 18m to advance clinical pipeline
/in News/by Thomas GabrielczykMaaT Pharma SA has announced 18m Series B financing to boost its microbiome biotherapeutics pipeline.
Stilla raises 20m in series B financing round
/in News/by Thomas GabrielczykFrench Stilla Technologies SA raised 20m in a Series B funding to boost digital PCR-based genetic testing.
Valneva raises US$85m
/in News/by Thomas GabrielczykFrench vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.
EMA greenlights 15 new meds
/in News/by Thomas GabrielczykThe EMAs human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.
Sleeping sickness target deciphered
/in News/by Thomas GabrielczykResearchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.